Shape your myeloma care: New MPE research highlights the power of shared decision-making in myeloma careMPE, Myeloma, Patient evidenceSeptember 2, 2025
The European Commission grants final authorisation for belantamab mafodotin (Blenrep®) combinations for relapsed/refractory myeloma patientslatest, Myeloma, NewsJuly 25, 2025
New guidelines for the treatment and the management of myeloma and smouldering myelomaMyeloma, NewsJuly 14, 2025
EMA CHMP gives positive opinion on daratumumab use in smouldering myeloma patients with high risk of developing myelomaAccess, MyelomaJune 27, 2025
European Commission approves linvoseltamab for the treatment of relapsed and refractory myelomaAccess, MyelomaApril 29, 2025
EMA CHMP gives positive opinion on linvoseltamab for relapsed/refractory myeloma patientsAccess, Myeloma, NewsMarch 3, 2025
